TP-05 (oral lotilaner)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a public biopharma company that achieved a significant milestone with the 2023 FDA approval of XDEMVY for Demodex blepharitis, a common eyelid disease affecting millions. The company is now executing its commercial launch while advancing a pipeline of novel candidates, including TP-03 for Meibomian Gland Disease and TP-04 for rosacea, based on its targeted therapeutic approach. Tarsus's strategy is to identify and develop treatments for prevalent, underserved conditions, aiming to establish a leading position in medical dermatology and ophthalmology.

Therapeutic Areas